Risk Factors Affecting Growth in Thalassemic Children at AUCH

Starting soon

Conditions studied: Thalassemia Majors (Beta-Thalassemia Major)

In brief

Thalassemia major is a hereditary hemoglobinopathy characterized by ineffective erythropoiesis and severe anemia, necessitating lifelong blood transfusions(1,2). Regular transfusions lead to iron overload, a primary driver of growth retardation in affected children. Iron accumulation in tissues like the pituitary and liver disrupts growth hormone secretion and insulin-like growth factor-1 production.

Key facts

Study ID

NCT07509996

Run by

Assiut University

People needed

85

Starts

2026-04-01

Expected to finish

2027-05-01

Last updated by the study team

2026-04-03

Who can join

Age: 1 and older, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Children aged 1 to 18 years diagnosed with β-thalassemia major based on hemoglobin electrophoresis or high-performance liquid chromatography (HPLC).
• Receiving regular blood transfusions as part of standard management at AUCH.
• Attending the hematology unit for at least one year prior to enrollment.

You may not qualify if…

• • Children with other types of thalassemia.
• Presence of congenital diseases, chronic illnesses other than thalassemia (e.g., malignancy, tuberculosis, chronic hepatitis, congenital heart disease, chronic renal failure, epilepsy, diabetes mellitus), or primary endocrinopathies.
• Patients with other causes of short stature, such as hereditary bone dysplasia or systemic disorders.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.